TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06175442

Intervention type: DEVICE
Intervention: Intraoperative intestinal decompression
Description: Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction

Intervention type: DEVICE
Intervention: Intraoperative intestinal decompression
Description: Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction

Intervention type: DEVICE
Intervention: Intraoperative intestinal decompression
Description: Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction

Intervention type: DEVICE
Intervention: Intraoperative intestinal decompression
Description: Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
Study: NCT06053775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS+OCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation
Description: tACS+OCT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tES sham
Description: tES sham + OCT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Cognitive Training
Description: OCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Cognitive Training
Description: OCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Cognitive Training
Description: OCT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Online Cognitive Training
Description: OCT
Study: NCT05705817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Soft Skills and Employment Training (ASSET)
Description: The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
Study: NCT05462106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose X
Description: Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose Y
Description: Administration of Dose Y of ACI-24.060
Study: NCT05709041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized lung-protective ventilation
Description: Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard lung-protective ventilation
Description: Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
Study: NCT05438498

Intervention type: DRUG
Group type: OTHER
Intervention: Evusheld (tixagevimab+cilgavimab) IM or IV
Description: Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Study: NCT06063239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Group
Description: Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: Subjects will receive orally administred probiotics based on placebo 90 days

Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
Study: NCT04860011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: Dapagliflozin 10mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets
Description: Metolazone 5MG or 10MG once daily
Study: NCT04593875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active LIFUP Treatment
Description: Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active LIFUP Treatment
Description: Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham LIFUP Treatment
Description: The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham LIFUP Treatment
Description: The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
Study: NCT06085287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Description: Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
Study: NCT04166656

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trumenba®
Description: Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bexsero®
Description: Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bexsero®
Description: Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
Study: NCT04702256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab administration
Description: Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
Description: IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of methylprednisolone, paracetamol and dexchlorpheniramine
Description: Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
Study: NCT05444426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Rehabilitation
Description: hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
Study: NCT04965272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 0.75 mg/day
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Description: Oral Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT05066958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: boost anti-viral immunity after T-cell depleted HSCT
Description: * Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening
Study: NCT06449859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC2938 Placebo
Description: TQC2938 Placebo is a placebo comparator
Study: NCT05618132

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acetylcholine rechallenge
Description: STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm).
Study: NCT06377072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenqi Sherong Pill
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
Study: NCT05767372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coherent Breathing Exercise
Description: Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths.
Study: NCT05517486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-101
Description: Bupivacaine HCl metered spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-101
Description: Bupivacaine HCl metered spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-101
Description: Bupivacaine HCl metered spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl subcutaneous injection
Description: Bupivacaine HCl, 50 mg/10 mL
Study: NCT05255302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab before randomization
Description: Pembrolizumab 200 mg every 3 weeks before randomization
Study: NCT05767372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks.
Study: NCT05255302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab before randomization
Description: Pembrolizumab 200 mg every 3 weeks before randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
Study: NCT05703373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement
Description: Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
Study: NCT05255302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab after randomization
Description: Pembrolizumab 200 mg every 3 weeks after randomization
Study: NCT06716385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSiHy Silicone Hydrogel Soft Contact Lens
Description: The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Silicone Hydrogel Contact Lenses (oA)
Description: The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
Study: NCT06217861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGM-R02b
Description: Administered as specified in the treatment arm.
Study: NCT04969211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VHX-896 and iloperidone
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone and VHX-896
Description: oral tablet
Study: NCT05966246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I : Experimental (Prucalopride succinate group)
Description: Experimental group taking prucalopride succinate from day 1 to day 5 after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm II : Control (Mosapride citrate group)
Description: Control gourp taking mosapride citrate from day 1 day 5 after surgery
Study: NCT05100108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy
Description: The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
Study: NCT05008172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splenic Artery Embolization
Description: The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
Study: NCT05666570

Intervention type: DEVICE
Intervention: Avelle NPWT
Description: wound management therapy
Study: NCT05171881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention for cerebral hypoxia
Description: For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
Study: NCT04714320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-AGT-LRx
Description: Multiple doses of IONIS-AGT-LRx will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Study: NCT04847349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OL-1, standard dose
Description: The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OL-1, high dose
Description: The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
Study: NCT05937984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Controlled Transcranial Magnetic Stimulation (cTMS)
Description: cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Controlled Transcranial Magnetic Stimulation (cTMS)
Description: A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
Study: NCT04927481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).